Centene vs Cvs Health
CNC and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNC and CVS compare
Cvs Health is the larger company, worth 3.4 times as much as Centene ($115B against $33.8B).
Centene grew revenue faster over the last twelve months (13.9% versus 7.4% for Cvs Health).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 1.2% compared with −2.5% at Centene.
Cvs Health pays a dividend yielding 2.2%; Centene does not pay one.
Cvs Health scores higher on the StockData Score (12 against 6 for Centene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNC | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $33.8B | $115B |
| Share price | $68.45 | $90.25 |
| Change, 1 year | 83.3% | 12.0% |
| Change, 5 years | −7.7% | −3.8% |
| Beta (5Y) | 0.50 | 0.47 |
| Employees | 61K | 300K |
| StockData Score | ||
| Total score | 6 | 12 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 23.9× |
| P/S | 0.2× (better) | 0.3× |
| P/B | 1.5× | 1.4× (better) |
| EV/EBITDA | – | 12.7× |
| P/FCF | 3.8× (better) | 9.8× |
| FCF yield | 26.5% (better) | 10.2% |
| Fair value | – | $77.92 |
| Margin of safety | – | −15.8% |
| Growth | ||
| Revenue growth (TTM) | 13.9% (better) | 7.4% |
| Revenue growth, 5Y average | 11.9% (better) | 8.4% |
| Net income growth (TTM) | −348% | 7.9% (better) |
| EPS growth (TTM) | −358% | 5.3% (better) |
| EPS growth, 5Y average | – | −23.9% |
| Profitability | ||
| Gross margin | 8.0% | 44.5% (better) |
| Operating margin | −2.8% | 2.0% (better) |
| Net margin | −2.5% | 1.2% (better) |
| FCF margin | 4.4% (better) | 2.8% |
| Return on equity | −20.4% | 6.2% (better) |
| Return on invested capital | −22.7% | 5.5% (better) |
| Financial health | ||
| Debt / equity | 0.71 (better) | 0.77 |
| Net debt / EBITDA | – | 3.70 |
| Interest coverage | −8.6× | 2.7× (better) |
| Current ratio | 1.15 (better) | 0.87 |
| Altman Z-score | 2.83 (better) | 2.45 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 2.2% |
| Payout ratio | – | 69.9% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 5.9% |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 98.8% | 89.2% |
| Held by insiders | 0.79% | 0.43% |
| Insider net buying, 12 months | −$14.6M (better) | −$324M |
| Superinvestors holding | 3 | 6 (better) |
| Short interest, % of float | 2.1% | 1.3% |
Go deeper
- CNC stock overview
- CNC income statement
- CNC valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.